TB-500 10 mg

$25.00

    Purity > 99% – View Lab Test

  • PeptideTB-500
  • Amount10 mg per vial
  • FormLyophilized powder
  • Purity≥99% (HPLC COA available)
  • ManufactureGMP-certified facility
  • Storage (dry)Cool, dry place
  • After reconstitution2–8 °C (short-term); ?20 °C for long-term

Out of stock

Description

TB-500 — Research Peptide (10 mg)

TB-500 is a synthetic analog of thymosin beta-4 (T?4), examined in
preclinical models for roles in cytoskeletal dynamics, cell migration, angiogenesis, and wound remodeling.
While it is frequently studied on its own, TB-500 is also a common research partner to
BPC-157, with TB-500 emphasizing actin-related motility and re-epithelialization biology.

What It Is

  • TB-500: 43-amino-acid analog of thymosin ?4, investigated for actin binding/sequestration,
    cell motility, microtubule/cytoskeleton remodeling, and re-epithelialization in injury models.

Proposed Mechanisms (Preclinical)

  • Actin-binding motif LKKTETQ associated with cytoskeletal reorganization and cell motility.
  • Wound-healing biology: re-epithelialization, angiogenesis, and granulation-tissue quality (model-dependent).
  • Inflammation-pathway modulation (e.g., miR-146a/IRAK1/TRAF6 axis, exploratory).

Selected Research Highlights

  • Skin/Wound Models: TB-500 (T?4) has been associated with faster re-epithelialization and
    contraction vs. controls in animal studies; small clinical datasets in chronic wounds have explored
    dose-response over multi-week protocols.
  • Tendon/Ligament: TB-family peptides have been reported to support more organized collagen
    and improved mechanical properties post-injury.
  • Muscle & Cardiac Models: Investigated for cytoskeletal remodeling and angiogenesis in
    skeletal-muscle injury and cardiac ischemia models.

Combining TB-500 with BPC-157 in Research

In many experimental frameworks, TB-500 is paired with BPC-157 to evaluate
complementary pathways: TB-500 for actin-based cell motility and re-epithelialization; BPC-157 for endothelial
integrity, angiogenic signaling, and matrix organization. Researchers may compare TB-500 alone vs.
TB-500 + BPC-157 to study potential additive effects on capillary density, ECM quality, and repair-related
signaling.
For teams that prefer a unified preparation, MyPurePeptide also provides a
BPC-157 & TB-500 Research Peptide Blend, allowing investigation of the combination
in a single co-formulated vial.

Chemical Information

  • TB-500 — Formula: C212H350N56O78S ·
    MW: 4963 g/mol
  • Content per vial: 10 mg TB-500 (lyophilized powder)

Specifications

  • Form: Lyophilized powder (research-grade)
  • Purity: ?99% (HPLC); COA per lot available
  • Packaging: Sealed vials suitable for laboratory handling

Storage & Handling

  • Store lyophilized vials in a cool, dry place, protected from light.
  • After reconstitution: refrigerate at 2–8 °C.
  • For long-term stability: store at ?20 °C; avoid repeated freeze–thaw cycles.

.mpp-prose .mpp-cols{
display:grid;
gap:14px;
}
@media (min-width:700px){
.mpp-prose .mpp-cols{
grid-template-columns:1fr 1fr;
}
}
.mpp-prose h2,
.mpp-prose h3{
margin:.2em 0 .35em;
}
.mpp-prose h4{
margin:.2em 0 .25em;
}
.mpp-prose ul{
margin:.2em 0 .6em;
padding-left:1.1em;
}
.mpp-prose p{
margin:.4em 0 .8em;
line-height:1.55;
}
.mpp-prose code{
background:#f6f8fb;
border:1px solid #e5e7eb;
border-radius:6px;
padding:.04em .35em;
}

Reviews

There are no reviews yet.

Be the first to review “TB-500 10 mg”

Your email address will not be published. Required fields are marked *